Novo Nordisk A/S, of Bagsvaerd, Denmark, reported top-line results from the sixth and last global phase IIIa trial, SUSTAIN6, assessing long-term cardiovascular and other safety outcomes of GLP-1 analogue semaglutide vs. placebo, both in addition to standard of care.